Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gritstone bio, Inc.GRTS · Entity 80946 | See Remarks | February 25, 2020 | February 27, 2020 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Chief Financial Officer | June 02, 2025 | June 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gritstone bio, Inc.
Report date February 25, 2020 · Filed February 27, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.91 · Expires 2030-02-24 | Direct | 110,000 |
Reported balance
After 2020-02-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-25 · Grant · Acquired 110,000 · Balance 110,000 F1: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on March 1, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on March 1, 2020.
IOVANCE BIOTHERAPEUTICS, INC.
Report date June 02, 2025 · Filed June 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,993 |
Reported balance
After 2025-06-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-02 · Exercise / conversion · Acquired 8,789 · Balance 64,993 F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. F2: Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 60,529 |
Reported balance
After 2025-06-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-06-02 · Tax withholding · Disposed 4,464 · Balance 60,529 F3: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F4: Represents common stock remaining after deducting the common stock withheld for taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 61,528 |
Reported balance
After 2025-06-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-02 · Exercise / conversion · Disposed 8,789 · Balance 61,528 F5: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6: The remaining RSUs will vest in equal quarterly installments. F7: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2: Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan.
F3: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F4: Represents common stock remaining after deducting the common stock withheld for taxes.
F5: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F6: The remaining RSUs will vest in equal quarterly installments.
F7: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2025 Filed Jun 4, 2025 20:46 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056432 · tm2517077-1_4seq1.xml · derivative · entry 3 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,528 Underlying: Common Stock · 8,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F6 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:46 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 4,464 | $1.76 | $7,856.64 |
DisclosureSEC source: 0001104659-25-056432 · tm2517077-1_4seq1.xml · nonDerivative · entry 2 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,529 F3 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F4 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:46 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 8,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056432 · tm2517077-1_4seq1.xml · nonDerivative · entry 1 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. F2 · balance_after: Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 01:05 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021866 · tm258333-6_4seq1.xml · derivative · entry 1 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,750 Underlying: Common stock · 93,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:33 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 58,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021062 · tm258333-5_4seq1.xml · derivative · entry 3 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,317 Underlying: Common Stock · 58,590 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F6 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:33 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 31,734 | $4.04 | $128,205.36 |
DisclosureSEC source: 0001104659-25-021062 · tm258333-5_4seq1.xml · nonDerivative · entry 2 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,204 F3 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F4 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:33 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 58,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021062 · tm258333-5_4seq1.xml · nonDerivative · entry 1 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. F2 · balance_after: Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:52 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 23,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097487 · tm2423453-1_4seq1.xml · derivative · entry 3 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,437 Underlying: Common Stock · 23,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The remaining RSUs will vest on the one-year anniversary of the initial grant date, as provided in footnote 7. F6 · derivative.expiration_date: The remaining RSUs will vest on the one-year anniversary of the initial grant date, as provided in footnote 7. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:52 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 11,891 | $10.85 | $129,017.35 |
DisclosureSEC source: 0001104659-24-097487 · tm2423453-1_4seq1.xml · nonDerivative · entry 2 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,348 F3 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F4 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:52 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 23,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097487 · tm2423453-1_4seq1.xml · nonDerivative · entry 1 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. F2 · balance_after: Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:51 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 46,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031106 · tm248017-2_4seq1.xml · derivative · entry 2 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,875 Underlying: Common stock · 46,875 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. F3 · derivative.expiration_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:51 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 105,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031106 · tm248017-2_4seq1.xml · derivative · entry 1 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,470 Underlying: Common stock · 105,470 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 22:24 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 168,750 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001104659-23-029093 · tm238642-1_4seq1.xml · derivative · entry 1 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,750 Underlying: Common Stock · 168,750 shares Expires 2033-03-02 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:45 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 18,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001600 · tm232380d1_4seq1.xml · derivative · entry 3 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 18,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: As of December 31, 2022, the remaining RSUs have fully vested and were settled on January 3, 2023. F6 · derivative.expiration_date: As of December 31, 2022, the remaining RSUs have fully vested and were settled on January 3, 2023. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:45 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 10,553 | $6.11 | $64,478.83 |
DisclosureSEC source: 0001104659-23-001600 · tm232380d1_4seq1.xml · nonDerivative · entry 2 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,801 F3 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities. F4 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:45 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 18,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001600 · tm232380d1_4seq1.xml · nonDerivative · entry 1 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This is the second and final vesting of the restricted stock units ("RSUs") issued on June 14, 2021. F2 · balance_after: Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 18,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071965 · tm2218629-2_4seq1.xml · derivative · entry 3 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,850 Underlying: Common stock · 18,850 shares Expires not disclosed F5 · security: Represents restricted stock units remaining after deducting the vested shares of common stock and common stock withheld for taxes as set forth in Table I above. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on December 31, 2022, the remaining restricted stock units shall vest and be settled on such date. F7 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on December 31, 2022, the remaining restricted stock units shall vest and be settled on such date. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 9,346 | $7.73 | $72,244.58 |
DisclosureSEC source: 0001104659-22-071965 · tm2218629-2_4seq1.xml · nonDerivative · entry 2 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,504 F3 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities. F4 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 18,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071965 · tm2218629-2_4seq1.xml · nonDerivative · entry 1 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This is the first vesting of the restricted stock units issued on June 14, 2021. F2 · balance_after: Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| January 14, 2022 Filed Jan 20, 2022 01:31 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $15.49 | $0.00 |
DisclosureSEC source: 0001104659-22-005596 · tm223806-1_4seq1.xml · derivative · entry 1 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2032-01-14 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:07 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 37,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082070 · tm2119923-4_4seq1.xml · derivative · entry 1 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,700 Underlying: Common stock · 37,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units vest as follows: (i) one-half of such shares shall vest and be settled on the one-year anniversary of the date of grant; and (ii) the remaining shares shall vest and be settled on December 31, 2022. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units vest as follows: (i) one-half of such shares shall vest and be settled on the one-year anniversary of the date of grant; and (ii) the remaining shares shall vest and be settled on December 31, 2022. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 11:07 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $50.26 | $0.00 |
DisclosureSEC source: 0001104659-20-136547 · tm2038660d2_4.xml · derivative · entry 1 Bellemin Jean-Marc · CIK 0001754253 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 150,000 shares Expires 2030-12-14 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 17:26 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $8.91 | $0.00 |
DisclosureSEC source: 0001567619-20-005027 · doc1.xml · derivative · entry 1 Bellemin Jean-Marc · CIK 0001754253 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2030-02-24 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on March 1, 2020. Read SEC document |
| February 13, 2019 Filed Mar 14, 2019 19:11 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 66,000 | $0.00 Strike: $12.02 | $0.00 |
DisclosureSEC source: 0001567619-19-006915 · doc1.xml · derivative · entry 1 Bellemin Jean-Marc · CIK 0001754253 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires 2029-02-12 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on March 1, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.